Kidney Infection Market

Kidney Infection Market Outlook 2031

The global kidney infection market size was USD 100.37 Billion in 2022 and is likely to reach USD 157.05 Billion by 2031, expanding at a CAGR of 5.1% during 2023–2031. The market growth is attributed to the growing geriatric population which is more susceptible to this infection.

The growing geriatric population is a major force driving the market. According to a report published by WHO, by 2030 1 in 6 people will be over the age of 60. This elderly population is more prone to kidney diseases due to declining health and weakened immune systems. For instance,

• According to recent reports published by John Hopkins University, over 50% of people aged 75 and above suffer from kidney infections.

Get Free Sample Report

Additionally, mental illnesses such as depression and anxiety are more prevalent among the elderly population, further affecting the functioning of the immune system. This diminished functioning results in problems such as inflammation and malnutrition which are predispositions to kidney-related illnesses. For instance,

• According to an October 2020 article published by NIH, individuals with an immune system more prone to inflammation are more likely to show symptoms related to major depression.

The research report finds that the COVID-19 pandemic bolstered the kidney infection market considerably. The illness as well as the treatment procedures for COVID-19, are shown to increase susceptibility towards chronic kidney disease.

The prevalence of kidney infection has also resulted in increased vulnerability to COVID-19. According to a report published by NIH in February 2023, 28—34% of hospitalized patients and 46—77% of patients in the ICU reported acute kidney infections due to COVID-19.

Impact of Artificial Intelligence (AI) on Kidney Infection Market

The rise of AI has streamlined the kidney infection market considerably. Personalized and home-based healthcare is now available for patients. This is especially convenient for elderly patients who are more immobile.

AI-powered monitoring systems provide real-time data on patient functioning. Use of AI in telemedicine can be used to monitor vital signs, health as well as overall functioning of the patient.  For instance,

• A report published by Oxford Academic in July 2023 reports on the use of an AI-based algorithm that has been developed to show symptoms of chronic kidney disease. It can be used to monitor patient data and report any anomalies that are related to the condition.

Kidney Infection Market Dynamics

Get Free Sample Report

Major Drivers

Growing susceptibility to kidney infections due to conditions such as diabetes and urinary tract infections drives the market.  These health conditions are related to an increasingly sedentary and unhealthy lifestyle.

According to a study conducted by the CDC in February 2022, 37 million adults across the US suffer from chronic kidney disease. A chronic, severe condition that hinders blood filtration. The growing rates of obesity due to increasingly unhealthy lifestyles in the US is expected to increase the prevalence of kidney infection in the coming years. 

Existing Restraints

Lack of medical and hygiene awareness in underdeveloped and developing regions is a major hindrance to the market. As a result of a lack of medical knowledge along with the paucity of government initiatives, a majority of the population in low-income nations are hesitant to approach medical facilities.

Emerging Opportunities

Improving efficacy of newly approved medications is projected to create new opportunities for the market during the forecast period. These groundbreaking medications are expected to revolutionize the industry and boost the home diagnostics market.

According to an article published by the Mayo Clinic in March 2023, the use of a new class of drugs known as SGLT 2 Inhibitors has shown considerable success in slowing down kidney infections.

Scope of Kidney Infection Market Report

The global market research report includes an assessment of the market trends, market segments, and regional markets. Overview and dynamics have also been included in the report.

Kidney Infection Market Segment Insights

Treatment Segment Analysis

Based on treatment, the kidney infection market is divided into medication, dialysis, kidney transplant, and other treatments. The medication segment is expected to dominate the market during the projection period.

The growth is attributed to the development of new, groundbreaking drugs that have halted the spread of kidney infections. The increased efficacy of drugs is expected to reduce the severity of kidney infection over the coming years thereby fueling their demand.  For instance,

• According to a report published by the FDA in April 2021, Farxiga, a drug originally used to treat diabetes, is proven to be extremely effective in treating kidney infections or more serious conditions such as chronic kidney disease.

The kidney transplant segment is also expected to show considerable growth during the projection period owing to the increasing cases of kidney transplants across the globe. The number of patients suffering from kidney infections preferring kidney transplants is rapidly increasing owing to advanced treatments such as steam cell treatment.  

It is a minimally invasive method of kidney transplant that is projected to reverse the damage caused by severe infections such as chronic kidney disease and kidney failure. Stem cell research is expected to replace the more invasive kidney transplant procedure over the coming years. For instance,

• According to an article published by NIH in July 2022, stem cells were used to repair the damage caused by kidney infections. The treatment was observed to be fairly effective and reduced the damage considerably.

End-User Segment Analysis

On the basis of end-user, the market is segmented into hospitals & clinics, nephrology centers, research institutes, and other institutes.

The hospitals & clinics segment is expected to be the dominating segment during the forecast period due to the increasing severity of kidney infections and the availability of advanced procedures in hospitals. Although minor infections can be healed with the help of antibiotics, severe cases require procedures such as dialysis that are specific to hospitals.

The research institutes segment is projected to register a considerable CAGR over the coming years due to the development of advanced procedures such as stem cell regeneration techniques to reverse the damage caused by kidney infections.

Advanced technologies such as CRISPR-Cas9 and stem cell research procedures can only be accessed by research institutions as these technologies still require considerable testing and modification before being approved by hospitals and medical organizations.

However, these tests are well underway and are expected to result in more productive approaches over the coming years. These developments are projected to drive the market considerably over the projected period.

Get Free Sample Report

Regional Outlook

In terms of region, the global kidney infection market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period due to the increasing prevalence of kidney infections. For instance,

• According to a June 2023 article by NIH, approximately 150 million individuals in the US suffer from kidney infections every year. The financial burden to treat this condition is a massive USD 5 billion.

Rising government initiatives for developing advanced healthcare devices, especially for the treatment of kidney infection is one of the factors for the market growth.  According to a report published by the American Healthcare Association in December 2020, the American government has allocated USD 175 billion for healthcare, out of which USD 70 billion was dedicated to hospitals.

The market in Asia Pacific is expected to register a considerable CAGR over the coming years owing to the growing population in middle and low-income regions. This large population along with the lack of awareness about hygienic practices has enabled the cases of kidney infections in these regions to grow rapidly. For instance,

• A report published by NIH in January 2022 stated that the populations in China and India are more susceptible to kidney infections. A massive 159 million adults in China and 140 million adults in India suffer from chronic kidney disease.

Get Free Sample Report

Segments

The global kidney infection market has been segmented on the basis of

Treatment

• Medication
• Dialysis
• Kidney Transplant
• Other Treatments

End-User

• Hospitals & Clinics
• Nephrology Centers
• Research Institutes
• Other Institutes

Region

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• AbbVie Inc.
• Akebia Therapeutics, Inc.
• Allergan plc.
• Amgen Inc.
• AstraZeneca
• F. Hoffman-La Roche Ltd.
• Johnson & Johnson Services, Inc.
• Kissei Pharmaceutical Co., Ltd.
• Maruishi Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.

Competitive Landscape

The competitive landscape of the global kidney infection market report provides key insights into the growth strategies and development initiatives implemented by the key players in the market.

Key players competing in the kidney infection market are AbbVie Inc.; Akebia Therapeutics, Inc.; Amgen Inc.; AstraZeneca; F. Hoffman-La Roche Ltd.; Johnson & Johnson Services, Inc.; Kissei Pharmaceutical Co., Ltd.; Maruishi Pharmaceutical Co., Ltd.; Pfizer Inc.; Sanofi; and Teva Pharmaceutical Industries Ltd.

These companies adopted development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide. The competitive landscape covers key insights into growth strategies adopted by major market players. For instance,

• In September 2022, Kissei Pharmaceutical Co., Ltd. along with Maruishi Pharmaceutical Co., Ltd. submitted an application for Difelikefalin for FDA to treat Hemodialysis.